Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT01017367 | Study of MDX-1100 (Anti-CXCL10 Human Monoclonal Antibody) in Combination With Methotrexate in Subjects With Active Rheumatoid Arthritis (RA) | PHASE2 | COMPLETED | 70 | — | — | Feb 1, 2008 | May 1, 2009 | Apr 23, 2010 | 18 | Romania, Ukraine |
| Arm | Type | Description |
|---|---|---|
| MDX-1100 | EXPERIMENTAL | MDX-1100 10 mg/kg administered i.v. over 60 minutes on days 1, 15, 29, 43, 57, and 71 |
| Placebo | PLACEBO_COMPARATOR | Placebo (saline) administered i.v. over 60 minutes on days 1, 15, 29, 43, 57, and 71 |
| Name | Type | Description |
|---|---|---|
| MDX-1100 | DRUG | MDX-1100 10 mg/kg i.v. over 60 minutes on days 1, 15, 29, 43, 57 and 71 |
| Placebo | DRUG | Placebo |
Inclusion Criteria: * Must meet the ACR criteria for RA * Must have active RA, characterized by at least 6 out of 66 swollen joints and 6 out of 68 tender joints, and at least 2 of the following: a serum C-reactive protein level greater than the upper limit of normal, an erythrocyte sedimentation r...